Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Free Cash Flow (2022 - 2025)

Incannex Healthcare's Free Cash Flow history spans 3 years, with the latest figure at -$4.6 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 18.18% to -$4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$18.4 million, a 16.63% decrease, with the full-year FY2025 number at -$12.5 million, up 22.12% from a year prior.
  • Free Cash Flow hit -$4.6 million in Q4 2025 for Incannex Healthcare, up from -$9.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for IXHL hit a ceiling of -$1.5 million in Q2 2025 and a floor of -$9.2 million in Q3 2025.
  • Historically, Free Cash Flow has averaged -$4.2 million across 3 years, with a median of -$4.0 million in 2024.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 63.15% in 2024 and later tumbled 316.59% in 2025.
  • Tracing IXHL's Free Cash Flow over 3 years: stood at -$2.2 million in 2023, then plummeted by 162.35% to -$5.7 million in 2024, then increased by 18.18% to -$4.6 million in 2025.
  • Business Quant data shows Free Cash Flow for IXHL at -$4.6 million in Q4 2025, -$9.2 million in Q3 2025, and -$1.5 million in Q2 2025.